Phase 3 Oesophageal Cancer Trial, Recruiting NCT04009265 Sponsor: Fujian Medical University Union Hospital Condition: Oesophageal Cancer
Back to Oesophageal Cancer

Phase 3 Oesophageal Cancer Trial, Recruiting

NCT04009265
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have volunteered to take part and have signed a consent form agreeing to participate
  • People who have had surgery to fully remove a tumour in the chest area of the oesophagus (food pipe), with lab tests confirming it was a type of cancer called squamous cell carcinoma
  • People who did not receive any cancer treatments before their surgery
  • People whose cancer, based on the 8th edition of a standard cancer staging system, has spread to nearby lymph nodes but not to distant parts of the body (specifically classified as pT1b-3N1-2M0) (confirm with trial site)
  • People with a general health and activity level rated as 0 or 1 on the WHO performance scale, meaning they are fully active or have only minor limitations in physical activity
  • People aged 18 to 75 years old, of any gender
  • People whose heart, liver, and kidney test results from within one week before starting treatment meet the required health standards

Who may not be able to join:

  • People whose surgery was performed using a left-sided chest surgical approach
  • People who experienced serious complications after surgery that prevent them from receiving further treatment
  • People who received other cancer treatments before joining the trial, or people who have another active cancer elsewhere in the body (with exceptions potentially made for certain non-melanoma skin cancers, cervical cancer that has not spread, or early prostate cancer that has been fully treated — confirm with trial site)
  • People with blood clotting problems, a tendency to bleed (such as an active stomach or intestinal ulcer), or who are currently taking blood-thinning or clot-dissolving medications
  • People with serious pre-existing heart conditions, including heart failure, difficult-to-control irregular heartbeats, unstable chest pain, a heart attack within the past six months, severe heart valve disease, or very hard-to-treat high blood pressure; or people with serious liver or kidney problems
  • People with uncontrolled neurological or mental health conditions that would make it difficult to cooperate with the study or accurately report how they are feeling during treatment
  • People with a known or suspected allergy to chemotherapy drugs used in this trial

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 26 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Chun Chen, MD, Fujian Medical University Union Hospital

Phone: +8659186218408

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Sponsor
Fujian Medical University Union Hospital
Registry
ClinicalTrials.gov
Start date
23 August 2019
Est. completion
1 July 2022

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Overall Survival; Overall Survival

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov